Company: SCYX
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001140361-25-016641
Chunk: 11

Company: SCYNEXIS INC
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 11
---
 currently held with SCYNEXIS, are as follows:

| Name                    |     | Age |     | Position Held With SCYNEXIS                     |
| Armando Anido           |     |  67 |     | Director                                        |
| David Angulo, M.D.      |     |  60 |     | Chief Executive Officer, President and Director |
| Steven C. Gilman, Ph.D. |     |  72 |     | Director                                        |
| Ann F. Hanham, Ph.D.    |     |  72 |     | Director                                        |
| David Hastings          |     |  63 |     | Director                                        |
| Guy Macdonald           |     |  66 |     | Chairman of the Board, Director                 |
| Philippe Tinmouth       |     |  61 |     | Director                                        |

If elected at the Annual Meeting, each of these nominees would be elected and qualified to serve until the 2026 annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner, until the director’s death, resignation or removal. It is our policy to encourage directors and nominees for director to attend the Annual Meeting. All of our current directors attended the 2024 annual meeting of stockholders. If any nominee becomes unavailable for election as a result of an unexpected occurrence, your shares will be voted for the election of a substitute nominee proposed by us. Each person nominated for election has agreed to serve if elected. Our management has no reason to believe that any nominee will be unable to serve. This Proposal 1 is to elect our seven nominees nominated as directors. The biographies of each of the nominees below contain information regarding the person’s service as a director, business experience, director positions held currently or at any time during the last five years, information regarding involvement in certain legal or administrative proceedings, if applicable, and the experiences, qualifications, attributes and skills of each director, including those that led to the Nominating and Corporate Governance Committee and the Board’s conclusion that the director should continue to serve as a director of SCYNEXIS. Armando Anido joined our Board on January 21, 2019. Mr. Anido served as Chairman of the board of directors and Chief Executive Officer of Zynerba Pharmaceuticals, a publicly-traded biopharmaceutical company, from October 2014 until it was acquired by Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) in October 202